Print
Email
SaveHealthline's Premium Tools
Healthline Part D Plan Selector
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
|
One day you woke up and said, "My eyes aren't what they used to be." Every one of us will experience changes in our eyes and vision with age.
|
|
A Phase II trial from Pfizer and its partner NicOx failed to meet its primary endpoint in studying PF 03187207 in patients with primary open-angle glaucoma or ocular hypertension.
|
|
Very small, complex catheters can now be inserted into small drainage structures within the eye, enabling glaucoma surgeons to enlarge these compromised outflow passages for the treatment of glaucoma.
|
|
NicOx S.A. has announced the results of a dose-ranging phase 2 study conducted with PF#8209;03187207 in Japanese patients with glaucoma by its partner Pfizer Inc.
|
|
French biotechnology firm Nicox said on Monday U.S. partner Pfizer had decided not to launch Phase III studies in Asia of an experimental treatment of glaucoma and ocular hypertension.
|
|
"It's just wow," said Lauren Morris . "I mean it's a huge difference." "They're just much more luminous, lustrous," said Monica Bifano .
|
|
For almost a decade, optometrists in Massachusetts have been fighting to offer glaucoma treatments and prescribe oral medication -- privileges that state law currently restricts to ophthalmologists.
|
|
Lexicon Pharmaceuticals said Wednesday it has began preclinical development of LX7101, a potential new drug for glaucoma.
|
|
International report - Allergan's proposed new product for stimulating natural growth in eyelashes may unleash a vibrant new cosmetic drug niche market.
|
|
Jul 30, 2008 - Othera Pharmaceuticals, Inc., announced today the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for OT-730, an oculoselective beta-blocker, as a ...
|
|
It doesn't take an advanced degree to figure out that the ophthalmologists didn't much like the bill, which would allow their lesser brethren, optometrists, to prescribe medications for certain eye conditions, ...
|
|
Donald Abrams, chief of Sinai Hospital's Department of Ophthalmology based at the Krieger Eye Institute.
|
|
Patients being treated for glaucoma with bimatoprost ophthalmic solution 0.03% , who use the drug to reduce IOP, have been noticing a surprising side effect: longer and thicker eyelashes.
|
|
U.S. Steel Corp. , America's largest steelmaker by market value, and Allergan Inc.
|
|
OTTAWAHealth Canada is warning consumers not to use some strengths of the prescription drug Sandoz Timolol Ophthalmic Solution because some bottles may contain more of the active ingredient than indicated on ...
|
|
AqueSys, a startup developing a device to treat glaucoma, has closed on $9 million in new funding, PE Hub reported Thursday.
|
 |
 |
Home | About | Health Experts | Careers | Site Map | Feedback | Help | Health Tools | Tell a Friend
Advertise | Terms of Use | Privacy Policy
Advertise | Terms of Use | Privacy Policy
Copyright © 2005 - 2008 Healthline Networks, Inc. All rights reserved.